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Abstract
Background: Haemodialysis patients are at increased risk of exposure to blood borne viruses. To reduce
transmission in the UK, all haemodialysis patients are regularly screened, and if susceptible to Hepatitis B virus (HBV)
infection, vaccinated.
Methods: This retrospective study was undertaken to determine the HBV immune status in a large dialysis cohort
and the prevalence of occult HBV infection, defined as the presence of anti-HBcore antibody (anti-HBcAb) and HBV
DNA without detectable HB surface antigen (HBsAg). Information on HBV status was retrieved from haemodialysis
patients under the care of The Royal Free Hospital, London, UK between 2009–2010. Available sera from 138 of 161
anti-HBcAb positive/HBsAg negative individuals were anonymised and tested for HBV DNA by a real time quantitative
PCR.
Results: 15 (2%) of 793 patients had chronic HBV infection (HBsAg positive). 161 (20%) were anti-HBcAb positive but
HBsAg negative suggesting past infection. 335 (54%) of the remaining 617 patients were considered immune following
vaccination (anti-HBsAb>10 IU/L). Three (2.2%) of the 138 anti-HBcAb positive, HBsAg negative patients had detectable
HBV DNA (3, 5 and 9 IU/ml). Standard liver function tests were normal in these patients.
Conclusions: In a large multi-ethnic London haemodialysis cohort, 20% patients had evidence of past HBV infection.
Despite this, the prevalence of occult HBV was found to be low and the very low levels of HBV DNA detected are unlikely
to pose a nosocomial transmission risk in the presence of robust vaccination and infection control measures.
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Background
Haemodialysis patients are at increased risk of infections
with blood-borne viruses (BBV), such as hepatitis B virus
(HBV), hepatitis C virus (HCV) and human immuno-
deficiency virus (HIV). Current UK guidelines recom-
mend that patients on haemodialysis are routinely tested
for BBV and that all dialysis centres implement measures
to prevent nosocomial transmission.
Many new infections with HBV are sub-clinical, and
current infection can be detected by the presence of
Hepatitis B surface antigen (HBsAg) in the serum [1].
Following the discovery that patients infected with HBV
could transmit infection within a haemodialysis unit, a
code of practice was introduced into the UK in the early
1970s, which dramatically reduced the incidence of HBV
infections in UK dialysis patients and staff [2]. UK gov-
ernment Department of Health (DOH) guidance recom-
mends that haemodialysis patients are screened 3
monthly for HBsAg, and chronic HBV patients are dia-
lysed in isolation using dedicated machines with strict
infection control measures to prevent nosocomial trans-
mission. Those patients returning from ‘dialysis away
from base’ in resource poor countries undergo enhanced
screening for HBsAg for 8 weeks [3].
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blood with or without anti-HB surface antibody (anti-
HBsAb) is considered as evidence of past HBV infection,
and these patients are considered non-infectious and
HBV DNA is therefore not routinely tested in this
group. However, occult HBV infection, defined as the
presence of anti-HBcAb and HBV DNA in blood with-
out any detectable HBsAg, has been described in these
‘HBV past infection’ patients. As such, it has been sug-
gested that there may be a potential risk of patients with
occult HBV transmitting infection within dialysis units,
as these patients are not isolated or segregated from
other dialysis patients.
One of the mainstays of preventing HBV transmission
within haemodialysis units is the establishment of a ro-
bust vaccination programme. Patients with chronic kid-
ney disease (CKD) exhibit specific and non-specific
defects in both humoral and cellular immune responses
[4]. As a result, the response to Hepatitis B vaccination
is lower in haemodialysis patients compared with the
general population. Vaccination is therefore advised early
in the course of the renal disease, using a double vaccine
dose (40 microgrammes) and a 4 rather than 3 dose
schedule [5]. It is estimated that 45–66% of patients with
CKD develop adequate anti-HBs responses, and however
levels decline more rapidly in comparison with immuno-
competent individuals [6]. Anti-HBsAb levels above
10 IU/L are considered to be protective.
Objectives
We wished to determine the HBV immune status of our
cohort and the prevalence of occult HBV infection in a
large inner city haemodialysis program following current
UK guidelines for HBV vaccination, and whether occult
HBV infection posed a potential risk for transmission
within a haemodialysis unit despite following national
policy.
Study design and methods
The study population comprised 793 adult patients
undergoing haemodialysis at The Royal Free Hospital
and its satellite dialysis units in 2009–2010. Demo-
graphic data on age and ethnic origin were collected
from the Renal database. A systematic search for Vir-
ology results (using the Pathology reporting system) was
carried out for each patient. Information was gathered
on the Hepatitis B surface antigen (HBsAg), core total
antibody (anti-HBc), surface antibody (anti-HBs), Hepa-
titis C and HIV status. Note was made of the date of ad-
ministration of each vaccination, and if no such record
existed, it was recorded as ‘no vaccination documented’.
The data was then analysed by initially identifying pa-
tients with current or past Hepatitis B infection and
categorising the remaining patients according to their
immune status i.e. those with an anti-HBs level>10 IU/L
were classified as immune versus <10 IU/L (non-
immune). Stored serum samples from anti-HBcAb
positive, HBsAg negative patients were anonymised
and tested for HBV DNA by an in-house real time
quantitative PCR assay with a lower level of detection
of 1.5 IU/ml [7].
Statistical analysis was performed using Chi Square
test with Yates Correction, using GraphPad Prism 5
Graph Pad, San Diego, USA). HBV immunity was com-
pared between the White ethnic group and other ethnic
groups (excluding the ‘not stated’ groups).
This retrospective audit complied with the UK National
Health Service (NHS) guidelines for clinical audit and
service development, and had appropriate approval.
Individual patient consent was waived by the Royal Free
Hospital Research and Development office as the audit
complied with NHS guidelines (UK NHS guidelines for
clinical audit and service development, available at http://
www.hra-decisiontools.org.uk/ethics/, and http://www.hra.
nhs.uk/research-community/before-you-apply/determine-
whether-your-study-is-research/). Anonymised data were
collected from virology laboratory tests that had been
performed as part of the routine clinical care of kidney
dialysis patients in keeping with the Royal Free Hospital
Trust policy and no patient identifiable data was used. No
children were included in this audit of adult patients.
Results
The demographic characteristics of the dialysis popula-
tion are shown in Figures 1 and 2. Age ranged from 23
to 99 years with a median of 66 years. Seventy nine per-
cent of the patients were ≥ 50 years of age (Figure 1 dis-
tribution of patient ages). This inner city patient cohort
came from a wide range of ethnic backgrounds (Figure 2
distribution of patient ethnicity).
Fifteen (2%) of the 793 patients were HBsAg positive
and anti-HBcAb positive for over at least 6 months or
more with detectable HBV DNA in blood indicating
chronic HBV infection. A total of 161 patients (20%)
were anti-HBcAb positive but HBsAg negative and were
therefore considered to have had past HBV infection
(Table 1). One hundred and thirty nine patients (86%)
also had HBsAb and the remaining 22 (14%) were iso-
lated HBcAb positive. Of note, patients with past HBV
infection were more likely to be from ethnic groups
other than White (79% other ethnic groups versus 18%
White (Table 2 distribution of patient ethnicity).
335 of the remaining 617 patients (54%; overall 42% of
793 patients) were immune to HBV through vaccination
with anti-HBsAb levels of >10 IU/L (Table 1). 282 pa-
tients (46%) were non-immune to HBV. The ethnicities
of those with vaccine induced immunity are presented in
Table 2. Analysis of our data showed that patients from
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to vaccination and developed immunity compared with
patients from the other ethnic groups (two-tailed p =
0.041).
Serum samples were available for HBV DNA testing
from 138 of the 161 patients who were anti-HBcAb
positive and HBsAg negative. Of these, 126 patients also
had anti-HBsAb. Three of 138 anti-HBcAb positive pa-
tients had very low levels of HBV DNA detected by PCR
(3, 5 and 9 IU/ml respectively). The prevalence of occult
HBV infection was therefore 2.2% in the test group, and
0.4% in the overall dialysis cohort. One patient was anti-
HBcAb positive/anti-HBs Ab positive (from ‘any other
ethnic group’) and two were isolated anti-HBc Ab posi-
tive (from ‘any other ethnic group- Greek’ and ‘other
Asian origin’- Chinese). Standard liver function tests
were within the normal reference ranges in all three of
these patients, and no patient had a history of liver dis-
ease, or co-infection with hepatitis C or blood transfu-
sion prior to the positive sample.
Twenty five (3%) out of the 793 patients had current
hepatitis C infection and were hepatitis C RNA positive.
The prevalence of HIV antibody positivity (with or with-
out HIV RNA suppression) in our cohort was 2% (16
out of 793).
Discussion
Occult Hepatitis B infection is characterized by the pres-
ence of HBV DNA without detectable HBsAg, with or
without the presence of HBV antibodies outside the
Figure 1 Distribution of patient age.
Figure 2 Distribution of patient ethnicity.
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mechanisms have been suggested for the pathogenesis of
occult Hepatitis B infection, although it is most likely
multifactorial, depending upon both host and viral fac-
tors. The majority of cases are secondary to overt HBV
infection and represent a residual low level viraemia
suppressed by a robust immune response, together with
abnormal histological findings on liver biopsy which de-
veloped either during the acute or chronic phase of HBV
infection [9,10].
In our study, a sensitive real time quantitative PCR
assay was used to determine the presence of occult
Hepatitis B infection in a large cohort of inner city adult
patients receiving maintenance haemodialysis. We did
find occult HBV, although the prevalence and levels of
detectable circulating HBV were low.
Some studies have observed a low level of occult HBV
in haemodialysis patients in countries that may not em-
ploy the isolation and screening policies in combination
with active vaccination followed in the UK. In a multi-
centre study of 289 haemodialysis patients in Tehran,
Iran, Aghakhani et al. reported that HBV DNA was de-
tected at levels <50 IU/ml in 9 of the 18 patients who
were anti-HBcAb positive/anti-HBsAb negative [11]. On
the other hand, Fabrizi et al. isolated anti-HBcAb in
20.8% of their Italian patients but did not find any cases
of occult HBV in their study group [12]. Similarly Jardim
et al. also did not detect HBV DNA in 34 haemodialysis
patients dialysing in Brazil who were anti-HBcAb posi-
tive [13].
In non-haemodialysis patients Kang et al., described 4
out of 230 Korean patients with ‘anti-HBcAb alone’ were
found to have very low levels of HBV DNA [14]. Vitale
et al. from Italy, set out to determine whether anti-
HBcAb in isolation can be used as a marker of ‘occult’
HBV in patients with or without HCV infection. The
patient group consisted of asymptomatic outpatients
referred for routine testing for viral hepatitis, drug users
and patients with hepatocellular carcinoma (HCC). A
total of 223 sera from non-haemodialysis patients were
found to have ‘anti-HBcAb alone’,a n do ft h e s e9
(4.0%) patients were found to have a detectable HBV
DNA [15].
The prevalence of HBV infection varies from country
to country, and as such one would expect that occult
HBV would similarly vary with geographic distribution.
Previous smaller studies have supported our findings
that overall rates of occult HBV in haemodialysis cohorts
appear to be low. In the vast majority of these occult ‘in-
fections’ the viral load levels are also consistently low.
Although in theory these patients may pose a nosoco-
mial transmission risk, the detection of HBV DNA does
not always indicate infectivity or disease progression,
therefore it has been proposed that a more comprehen-
sive term such as ‘occult Hepatitis B’ rather than ‘occult
Hepatitis B infection’ is used [16].
Table 1 Hepatitis B status of our haemodialysis cohort
Hepatitis B surface anigen
(HBsAg)
Hepatitis B core antibody
(anti-HBcAb)
Hepatitis B surface antibody
(anti-HBsAb)
Number of
patients
HBV immune via
vaccination
Negative Negative Positive 335 (42%)
Chronic HBV infection Positive Positive Negative 15 (2%)
Past Hepatitis B
infection
Negative Positive Positive 139 (17%)
Past Hepatitis B
infection*
Negative Positive Negative 22 (3%)
Non-immune Negative Negative Negative 282 (36%)
*Patients who have acquired natural immunity due to prior exposure to hepatitis B.
Table 2 ‘Past’ versus ‘Vaccine-induced’ immunity in the different ethnic groups of the dialysis cohort
Ethnicity Past hepatitis B infection Vaccine induced immunity
White (British, Irish, any other white) 29 147
Black (African, Caribbean, any other black) 73 77
The Indian Subcontinent (Indian, Pakistani, Bangladeshi) 19 49
Any other Asian (incl. Chinese) 16 25
Any other ethnic origin 15 26
Mixed Ethnicity 44
Not stated 57
TOTAL NO. 161 335
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blood that may lead to transmission in the haemodialysis
setting. The UK Department of Health guidelines rec-
ommend that HBV infected healthcare workers can be
allowed to perform exposure prone procedures if their
HBV DNA level is suppressed to <1,000 copies/ml
(around 250 IU/ml) [17].
Although we follow the current UK practice of isolating
patients with chronic hepatitis B infection, and implement
practices designed to prevent nosocomial infection within
our dialysis centres, we did detect a number of patients
with occult hepatitis B which may reflect our inner city,
multi-ethnic practice, as in our haemodialysis cohort,
62.5% of patients are considered HBV immune, either
through vaccination of due to past infection. Although we
could detect circulating HBV in a small number of HBsAg
negative patients, the low levels of circulating HBV DNA
we detected in our cohort are unlikely to pose a real risk
of nosocomial transmission in clinical practice based on
following universal precautions, and particularly if a ro-
bust HBV vaccination programme is implemented in
haemodialysis units. However it is especially important
that vaccination is provided early in patients with CKD
thought to be at risk of requiring renal replacement ther-
apy, as it has been shown that these individuals have an
impaired response to vaccination once established on
haemodialysis. In our cohort, patients from the Caucasoid
ethnic group showed better vaccination-induced immune
response than patients from other ethnic groups (p=
0.041). The ethnic difference in vaccine response is not
well understood, although a recent study suggests that cer-
tain human leukocyte antigen (HLA) tissue types are asso-
ciated with non-responsiveness to HBV vaccination and
that different HLA types of the ethnic groups should be
considered when evaluating vaccine responses [18].
Conclusions
The strength of our audit is our large multi-ethnic haemo-
dialysis cohort in North Central London, with 20% of pa-
tients having evidence of previous infection with HBV.
Despite this, the prevalence of patients having circulating
detectable HBV viraemia (occult HBV) was found to be
low and the reassuringly the very low levels of HBV DNA
detected are very unlikely to pose a nosocomial transmis-
sion risk to other kidney haemodialysis patients in the
presence of robust active vaccination program against
HBV and appropriate infection control measures. As we
only measured HBV on one occasion the limitation of our
study is that we cannot exclude that at other times pa-
tients may have higher circulating viral DNA levels and
may pose a risk of blood borne infection which could be
increased in centres without an active vaccination pro-
gram or infection control policies.
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